South Africa remains at the epicentre of the HIV epidemic, but a game-changing tool is coming. Lenacapavir, the world’s first twice-yearly HIV prevention injection, has been approved by the South African Health Products Regulatory Authority (SAHPRA) — a major step toward making it available in public clinics from April 2026.
Lenacapavir, developed by Gilead Sciences, is a long-acting antiretroviral that provides six months of protection against HIV with a single injection. Clinical trials have shown it to be among the most effective prevention options available, offering a discreet and convenient alternative to daily PrEP pills. Its long-acting nature could overcome many of the adherence challenges associated with daily oral PrEP, making it especially valuable for young people and key populations who face barriers to consistent pill-taking.
The South African government, with R520 million in Global Fund support, plans to begin a phase-one rollout across 23 high-incidence districts in six provinces, targeting around 360 clinics and up to 456,000 people in the first two years. Minister of Health Dr. Aaron Motsoaledi affirmed the government’s commitment to make lenacapavir “a public good — accessible, affordable, and locally produced.”
With many years of experience in PrEP delivery, key population programming, and health systems strengthening, Anova Health Institute looks forward to supporting the rollout of this breakthrough prevention tool and ensuring equitable access for those who need it most.
Header image: © Gilead Sciences
